Approved phase II
Immunicum AB (publ) today announced that the Swedish Medical Products Agency has granted the Company’s application to commence a phase II clinical trial in patients with renal cell carcinoma with the therapeutic cancer vaccine INTUVAX in Sweden. In addition to an approval from the Ethics Committee to start the trial in Sweden, Immunicum will also need clearance from a number of other European regulatory authorities to start enrollment of patients in more countries during spring 2015.
Read the press release here: Press release 150217 – phase II
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805